School of Basic Sciences

Dr. Soumendra Rana

Associate Professor
Brief Resume
Personal Website
Research Interests:
Structure Function Studies on Peptide or Protein binding G-protein Coupled Receptors. Rational Design of Peptides / Proteins as Therapeutics (Antimicrobial / Antiviral / Anti-inflammatory).Chemical and Cellular Biology. Computational Biology.
Education
Degree Discipline Year School
  Ph.D. Molecular Biophysics 2007 Indian Institute of Technology Bombay
  • Advanced Instrumentation Lab (CY5P004)
  • Biochemistry (CY7L001)
  • Biosciences (CYA2001)
  • B. Tech Chemistry Lab (CY1P001)
  • Chemistry (CY1L001)
  • Chemical Biology of Receptors (CY7L016)
  • Computational Methods & Application (CY5L009)
  • Genetic Engineering (CY3L001)
  • Introduction to Biosciences & Technology (ID2L001)
  • Organic Chemistry Lab (CY5P001)
  • Physical Methods in Inorganic Chemistry (CY7L006)
  • Receptor Pharmacology & Drug Discovery (CY7L020)
  • Structure Function of Biomolecules (CY7L019)
Ph.D: 5 graduated; 1 (Submitted), 4 continuing
M.Sc: 11 graduated; 1 continuing
B.Tech: 1 completed
Winter Interns: 5 completed
Summer Interns: 1 completed
  • Associate Editor, Journal of Molecular Histology (Springer Nature)
  • Member of the International Chemical Biology Society
  • Life Member of Society of Biological Chemists, India
  • Life Member of Indian Peptide Society
  • Life Member of American Peptide Society
  1. Rational Design, Synthesis, Structural and Biological Evaluations of Non-coded Amino acid (NCAA) Containing Peptides as Potential Anti-inflammatory and Antimicrobial Agents; (Under evaluation, SERB)
  2. Rational Design of Targeted Peptide Antibodies against hC5a, including Broad Spectrum Antiviral Peptides Potentially Targeting SARS-CoV-2  Spike Protein (Apr-Dec 2020); Sponsoring Agency-IIT Delhi, India.
  3. Structural Studies on the Interaction of hC5a with the N-terminus Peptides of C5aR and C5L2 Receptor (2017-2020); Sponsoring Agency-DST, New Delhi, India
  4. Structure-Function studies of Extra Cellular Loop 2 (ECL2) of C5aR and C5L2 receptors (2013-2015); Sponsoring Agency-IIT Bhubaneswar, India
  1. Singh, A.; Shadangi, S.; Rana, S. G-protein Coupled Receptors in Neuroinflammation, Neuropharmacology, and Therapeutics. 2025 (Under review).
  2. Shadangi, S.; Singh, A.; Rana, S. Deciphering the Mechanism of Action of a Short, Synthetic Designer AMP against Gram-negative Bacteria. Biopolymers, 2025, 116(3):e70019.
  3. Gupta, P.; Singh, A.; Rana, S. Interaction of Phosphorylated C5aR1 with β-Arrestin1: A Comparative Structural Modeling Study. Proteins, 2025 (Under revision)
  4. Singh, A.; Shadangi, S.; Gupta, P.; Rana, S. Type II Diabetes Mellitus: A Comprehensive Review of Pathophysiology, Comorbidities, and Emerging Therapies. Comprehensive Physiology, 2025, 15(1):e70003.
  5. Ghosh, M; Gupta, P. K.; Jena, S.; Rana, S. The Interaction of Methotrexate with the Human C5a and its Potential Therapeutic Implications. 2024 (Under review).
  6. Ghosh, M; Gupta, P. K.; Behera, L. M.; Rana, S. Structure of Designer Antibody-like Peptides Binding to the Human C5a with Potential to Modulate the C5a Receptor Signaling. J. Med. Chem. 2024 (In press).
  7. Behera, L. M.; Gupta, P. K.; Ghosh, M; Shadangi, S; Rana, S. A Rationally Designed Synthetic Antiviral Peptide Binder Targeting the Receptor Binding Domain of SARS-CoV2. J. Phy. Chem. B. 2024, 128(19):4631-4645.
  8. Gupta, P.; Singh, A.; Rana, S. Conformational variants of the Ternary complex of C5a, C5aR1, and G-protein. J. Bimol. Struct. Dyn. 2024, DOI: 10.1080/07391102.2024.2305698
  9. Ghosh, M.; Shadangi, S.; Rana, S. Rational Design of Antibody-like Peptides for Targeting the Human Complement Fragment Protein C5a. Proteins, 2024; 92(4):449-463.
  10. Behera, L. M.; Ghosh, M; Gupta, P. K.; Rana, S. A Rationally Engineered Small Antimicrobial Peptide with Potent Antibacterial Activity. J. Cell. Biochem. 2024, 125(2):e30503
  11. Gupta, P.; Das, A.; Singh, A.; Rana, S. Ternary Model Structural Complex of C5a, C5aR2, and Beta-Arrestin1. J. Bimol. Struct. Dyn. 2023, http://dx.doi.org/10.1080/07391102.2023.2239927.
  12. Ghosh, M.; Rana, S. The anaphylatoxin C5a: Structure, Function, Signaling, Physiology, Disease, and Therapeutics. Int. Immunopharmacol. 2023, 118, 110081.
  13. Das, A.; Ghosh, M.; Gupta, P.; Rana, S. Neutraligands of C5a can Potentially Occlude the Interaction of C5a with the Complement Receptors C5aR1 and C5aR2. J. Cell. Biochem. 2023, 124 (2), 266-281.
  14. Das, A.; Gupta, P.; Rana, S. C5aR2 Receptor: The Genomic Twin of the Flamboyant C5aR1. J. Cell. Biochem. 2022, 123(11), 1841-1856.
  15. Behera, L. M.; Ghosh, M.; Rana, S. Deciphering the Conformational Landscape of Few Selected Aromatic Non-Coded Amino acids (NCAAs) for Applications in Rational Design of Peptide Therapeutics. Amino Acids, 2022, 54, 1183-1202.
  16. Das, A.; Behera, L. M.; Rana, S. “Interaction of Human C5a with the Major Peptide Fragments of C5aR1: Direct Evidence in Support of a “Two-Site” Binding Paradigm”. ACS Omega, 2021, 6(35): 22876-22887.
  17. Das, A.; Rana, S. “The Role of Human C5a as a Non-genomic Target in Corticosteroid Therapy for Management of severe COVID19”. Comput. Biol. Chem. 2021, 92, 107482.
  18. Mishra, R.; Behera, L. M.; Rana, S. “Binding of Raloxifene to Human Complement fragment 5a (hC5a): A Perspective on Cytokine Storm and COVID19”. J. Bimol. Struct. Dyn. 2020, 15, 1-13.
  19. Mishra, R.; Das, A.; Rana, S. “Resveratrol Binding to Human Complement fragment 5a (hC5a) may Modulate the C5aR Signaling”. J. Bimol. Struct. Dyn. 2020, 17, 1-15.
  20. Mishra, R.; Rana, S. “A Rational Search for Discovering Potential Neutraligands of Human Complement fragment 5a (hC5a).” Bioorg. Med. Chem. 2019, 27, 115052
  21. Sahoo, A.; Mishra, R.; Rana, S. “The Model Structures of the Complement Component 5a Receptor (C5aR) Bound to the Native and Engineered hC5a.” Sci. Rep. 2018, 8, 2955.
  22. Rana, S.; Sahoo, A.; Majhi, B. “Structural Complexes of Agonist, Inverse Agonist and Antagonist Bound C5a Receptor: Insights into Pharmacology and Signaling.” Mol. BioSyst. 2016, 12, 1586-1599.
  23. Rana, S.; Sahoo, A.; Majhi, B. “Allosterism in human Complement Component 5a (hC5a): A Damper of C5a Receptor (C5aR) Signaling.” J. Bimol. Struct. Dyn. 2015, 1-13.
  24. Rana, S.; Sahoo, A. “Model structures of inactive and peptide agonist bound C5aR: Insights into agonist binding, selectivity and activation.” Biochem. Biophy. Rep. 2015, 1, 85-96.
  25. Kumar SS; Rana S; Nangia A. “Solid-state form screen of cardiosulfa and its analogues”. Chem Asian J. 2013, 8, 1551-68.
  26. Akiri, K.; Cherukuvada, S.; Rana, S.; Nangia, A.”Crystal Structures of Pyridine Sulfonamides and Sulfonic Acids.” Cryst. Growth Des. 2012, 12, 4567-73.
  27. Rana, S.; Yang, L; Hassanian, S. M.; Rezaie A. R. “Determinants of the Specificity of Protease-activated Receptors-1 and 2 Signaling by Factor Xa and Thrombin.” J. Cell. Biochem. 2012, 113, 977-84.
  28. Rana, S.; Baranski, T. J. “Third Extracellular Loop (EC3)-N terminus Interaction is Important for 7TM Receptor Function: Implication for an Activation ‘Microswitch’ Switch Region.” J. Biol. Chem. 2010, 285, 31472-83.
  29. Rana, S.; Kundu, B.; Durani, S. “A Synthetic Cholinergic Receptor of Mixed-L, D Residues Exceptionally Small and Simple.” Biopolymers 2007, 87, 231-243.
  30. Rana, S.; Kundu, B.; Durani, S. “A Double Catgrip Mixed L and D Mini Protein Only 20 Residues Long.” Bioorg. Med. Chem. 2007, 15, 3874-3882.
  31. Joshi, S.; Rana, S.; Wangikar, P.; Durani, S. “Computational Design of Proteins Stereochemically Optimized in Size, Stability and Folding Speed”. Biopolymers 2006, 83, 122-134. (Designed THBs were Featured on the Cover Page of Biopolymers).
  32. Rana, S.; Kundu, B.; Durani, S. “A Small Peptide Stereochemically Customized as a Globular Fold with a Molecular Cleft”. Chemical Communications 2005, 11, 207-209. (Featured as Hot article by Royal Society of Chemistry and as news in Chem. Sci. and Chemistry World, Dec 26, 2004)
  33. Rana, S.; Kundu, B.; Durani, S. “Stereospecific Peptide Folds. A Rationally Designed Molecular Bracelet.” Chemical Communications 2004, 21, 2462-2463.
Patents
  1. Rana S., An Engineered Antimicrobial Peptide (AMP), Patent pending (No: 202331049857)

1: Washington University School of Medicine in Saint Louis, Missouri, USA, 2: Saint Louis University School of Medicine, Missouri, USA, 3: University of Arizona, Tucson, Arizona, USA

Patents

  1. Rana S., An Engineered Antimicrobial Peptide (AMP), Patent pending (No: 202331049857)
Scroll to Top
Skip to content